Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) Enterprise Value (2018 - 2025)

Revolution Medicines has reported Enterprise Value over the past 8 years, most recently at -$2.0 billion for Q4 2025.

  • Quarterly results put Enterprise Value at -$2.0 billion for Q4 2025, up 11.52% from a year ago — trailing twelve months through Dec 2025 was -$2.0 billion (up 11.52% YoY), and the annual figure for FY2025 was -$2.0 billion, up 11.52%.
  • Enterprise Value for Q4 2025 was -$2.0 billion at Revolution Medicines, down from -$1.9 billion in the prior quarter.
  • Over the last five years, Enterprise Value for RVMD hit a ceiling of -$461.4 million in Q2 2022 and a floor of -$2.3 billion in Q4 2024.
  • Median Enterprise Value over the past 5 years was -$909.6 million (2023), compared with a mean of -$1.2 billion.
  • Biggest five-year swings in Enterprise Value: increased 28.61% in 2022 and later crashed 187.31% in 2023.
  • Revolution Medicines' Enterprise Value stood at -$577.1 million in 2021, then dropped by 11.76% to -$644.9 million in 2022, then crashed by 187.31% to -$1.9 billion in 2023, then decreased by 23.55% to -$2.3 billion in 2024, then increased by 11.52% to -$2.0 billion in 2025.
  • The last three reported values for Enterprise Value were -$2.0 billion (Q4 2025), -$1.9 billion (Q3 2025), and -$2.1 billion (Q2 2025) per Business Quant data.